| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute meningoencephalitis in a patient with COVID-19
|
Chaumont, H.
|
|
|
176 |
6 |
p. 519-521
|
artikel
|
| 2 |
Covid-19 and Guillain-Barré syndrome: More than a coincidence!
|
El Otmani, H.
|
|
|
176 |
6 |
p. 518-519
|
artikel
|
| 3 |
COVID-19 and ischemic stroke: Should we systematically look for lupus anticoagulant and antiphospholipid antibodies?
|
Aubignat, M.
|
|
|
176 |
6 |
p. 505-506
|
artikel
|
| 4 |
COVID-19 may induce Guillain–Barré syndrome
|
Camdessanche, J.-P.
|
|
|
176 |
6 |
p. 516-518
|
artikel
|
| 5 |
Depression could modulate neuropsychological status in epilepsy
|
Forthoffer, N.
|
|
|
176 |
6 |
p. 456-467
|
artikel
|
| 6 |
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment
|
Ouallet, J.-C.
|
|
|
176 |
6 |
p. 500-504
|
artikel
|
| 7 |
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? No
|
Labauge, P.
|
|
|
176 |
6 |
p. 494-496
|
artikel
|
| 8 |
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes
|
de Seze, J.
|
|
|
176 |
6 |
p. 497-499
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
176 |
6 |
p. i
|
artikel
|
| 10 |
Erratum to “What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature” [Rev. Neurol. 176 (4) (2019) 235–243]
|
Pourcher, V.
|
|
|
176 |
6 |
p. 526
|
artikel
|
| 11 |
Etiological assessment of status epilepticus
|
Valton, L.
|
|
|
176 |
6 |
p. 408-426
|
artikel
|
| 12 |
First case of Covid-19 presented with cerebral venous thrombosis: A rare and dreaded case
|
Hemasian, H.
|
|
|
176 |
6 |
p. 521-523
|
artikel
|
| 13 |
Genetic/idiopathic generalized epilepsies: Not so good as that!
|
Nilo, A.
|
|
|
176 |
6 |
p. 427-438
|
artikel
|
| 14 |
Getting older with chronic temporal lobe epilepsy: What memory profile?
|
Samson, S.
|
|
|
176 |
6 |
p. 439-443
|
artikel
|
| 15 |
Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network
|
Solé, G.
|
|
|
176 |
6 |
p. 507-515
|
artikel
|
| 16 |
Lennox-Gastaut syndrome: New treatments and treatments under investigation
|
Auvin, S.
|
|
|
176 |
6 |
p. 444-447
|
artikel
|
| 17 |
Long-term cognitive outcomes in patient with epilepsy
|
Forthoffer, N.
|
|
|
176 |
6 |
p. 448-455
|
artikel
|
| 18 |
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
|
Louapre, C.
|
|
|
176 |
6 |
p. 523-525
|
artikel
|
| 19 |
Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? No
|
Kremer, S.
|
|
|
176 |
6 |
p. 485-486
|
artikel
|
| 20 |
Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? Synthesis
|
Durand-Dubief, F.
|
|
|
176 |
6 |
p. 490-493
|
artikel
|
| 21 |
Should spinal cord MRI be systematically performed for diagnosis and follow up of multiple sclerosis? Yes
|
Kerbrat, A.
|
|
|
176 |
6 |
p. 487-489
|
artikel
|
| 22 |
Social cognition in epilepsy: State of the art and perspectives
|
Mirabel, H.
|
|
|
176 |
6 |
p. 468-479
|
artikel
|
| 23 |
The future of epilepsy
|
Dupont, S.
|
|
|
176 |
6 |
p. 407
|
artikel
|
| 24 |
Wearable devices for seizure detection: Is it time to translate into our clinical practice?
|
Rheims, S.
|
|
|
176 |
6 |
p. 480-484
|
artikel
|
Tijdschrift beschrijving